Missouri Avenue & Conley Avenue
Columbia, MO MO 65211
United States
University of Missouri School of Law
SSRN RANKINGS
in Total Papers Downloads
new drugs, patents, data exclusivity, clinical trials, medical innovation, health policy, empirical research, history of medicine, patent policy, patent term restoration
cannabis, marijuana, medical marijuana, FDA, food and drug law, health law, regulatory law, administrative law
patents, pharmaceuticals, patent term restoration, innovation, access to medicines, clinical research, empirical research
Generics, Brand Drugs, Hatch-Waxman, Antitrust, Intellectual Property, Patents, Biosimilars, Authorized Generics, New Drugs, FDA, PTO
drugs, patents, generic drugs, patent term restoration, patent term extension, public choice
pharmaceuticals, drugs, generic drugs, access to medicines, biologics, biosimilars, intellectual property, patents, exclusivity, data protection
biosimilars, BPCIA, biologics, Hatch-Waxman
Generic Drugs, Biosimilars, Patents, Antitrust, Coverage, Reimbursement, Substitution, Marketplace Dynamics, Competition, Medicare, Medicaid
drugs, patents, evergreening, exclusivity, policymaking
drugs, biologics, medicine, generic drugs, biosimilars, patents, exclusivity, new uses, repurposing, innovation policy
biosimilars, BPCIA, FDA, biologics
drugs, patents, generic drugs, FDA, evergreening, antitrust
FDA, brand drugs, generic drugs, drug patents, trademark law, brand names, pharmacy law, healthcare finance, history of pharmacy, history of medicine, evergreening, Medicare, Medicaid, food and drug law
Generic Drugs, Biosimilars, Antitrust, Patent, Legislation, FDA, Drug Pricing, Innovation Policy, Biologics
fecal microbiota, FDA, new drugs, tissues, blood, Hatch Waxman, orphan drugs, cost-benefit analysis, innovation
Hatch-Waxman, 180-day exclusivity, generic drugs, ANDAs
Antitrust, Competition, Generic Drugs, Biosimilars, Patents, Exclusivity, Product Hopping, Incremental Innovation, Competition, Innovation
transparency, trade secrets, clinical data, data protection
FDA, Patent, Antitrust, Drug Pricing, Generic Drugs, Public Health, Transparency, Open Government
patents, medical devices, innovation, FDA, intellectual property, drugs, drug patents
biologics, medicines, innovation, patent litigation, economics, FDA, Hatch-Waxman, legislation
advisory committees, FDA, conflicts of interest
preemption, FDA, products liability
outpatient commitment, mental health, O'Connor v. Donaldson
biosimilars, generic drugs, BPCIA, Hatch-Waxman, price competition, innovation, cost savings, pharmaceuticals, biotechnology
